그리폴스 (GRFS) 주가

그리폴스(GRFS)는 NASDAQ에 상장된 Healthcare · Drug Manufacturers - General 기업입니다. 현재가 $7.78 (-1.89%), 시가총액 $5.28B, PER 10.78, 52주 범위 $7.49 ~ $10.85.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived

핵심 지표

• 현재가: $7.78 (-1.89%)
• 시가총액: $5.28B
• PER (주가수익비율): 10.78
• 52주 최저~최고: $7.49 ~ $10.85
• 섹터: Healthcare
• 산업: Drug Manufacturers - General
• 거래소: NASDAQ

그리폴스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

그리폴스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.89
• 순이익률: 0.06%
• 영업이익률: 0.16%
• 배당수익률: 0.02%

자주 묻는 질문